Aligos Therapeutics will present latest poster of its CAM-E drug candidate ALG-000184 at The Liver Meeting® 2023

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS) is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat liver and , a company with unmet medical needs in viral diseases, today announced that the abstract for its capsid assembly modulator-null (CAM-E) drug candidate ALG-000184 has been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting® Poster, November 10-14, 2023 in Boston, MA.

Poster (#5028-C) titled “Chronic administration of the capsid assembly modulator ALG-000184 induces polylog reductions in DNA, RNA, HBsAg, HBeAg, and HBcrAg in untreated HBeAg-positive chronic hepatitis B subjects ” will be presented in Poster Hall C on Monday, November 13, from 1-2 pm ET. The report was authored by Dr. (MF) Yuen, Chairman and Professor of the Department of Gastroenterology and Hepatology at the University of Hong Kong.

About Arrigos

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 with a mission to become a world leader in the treatment of liver and viral diseases. Aligos’ strategy is to leverage its team’s deep expertise and decades of drug development experience in liver and viral diseases to discover and develop drugs targeting non-alcoholic steatohepatitis (NASH) and viruses with high unmet medical need, such as potential best treatments for coronaviruses and chronic viruses). Hepatitis B (CHB).

forward-looking statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be deemed “forward-looking statements.” Forward-looking statements are often, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate” and other similar words. “Expectations” and other similar terms referring to future results. Such forward-looking statements are subject to significant risks and uncertainties that could cause our development plans, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the proposed financing, risks and uncertainties inherent in the drug development process, including the clinical development of Aligos stages, the process of designing and conducting clinical trials, the regulatory approval process, the timing of regulatory filings, challenges related to the production of drug products, Aligos’ ability to successfully establish, protect and defend its intellectual property rights, and other matters that may affect the adequacy of Aligos’ operations. capital resources to fund, reliance on third-party manufacturing and development work, and the impact of global events and other macroeconomic conditions on Aligos’ business. There are risks and uncertainties related to the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements. For a further description of the risks associated with Aligos’ business in general, please see Aligos’ quarterly report on Form 10-Q filed with the SEC on August 3, 2023 and future periodic reports to be filed with the SEC Except as required by law, Aligos assumes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

The story continues

Media Contact

Veronica Eames
Life Sciences Newsletter
Veames@lifescicomms.com

Investor Contact
Dr. Corey Davis
life sciences consultant
+1 212 915 2577
cdavis@lifesciadvisors.com